Candel Therapeutics Inc (CADL)vsModerna Inc (MRNA)
CADL
Candel Therapeutics Inc
$11.29
-4.73%
HEALTHCARE · Cap: $806.89M
MRNA
Moderna Inc
$182.11
-0.25%
HEALTHCARE · Cap: $69.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 7186997% more annual revenue ($2.23B vs $31,000). CADL leads profitability with a 0.0% profit margin vs -141.4%. CADL earns a higher WallStSmart Score of 22/100 (F).
CADL
Avoid22
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CADL.
Margin of Safety
+69.9%
Fair Value
$134.69
Current Price
$182.11
$47.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 10.7x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CADL
CADL has a balanced fundamental profile.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : CADL
The primary concerns for CADL are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
CADL profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
CADL generates stronger free cash flow (-17M), providing more financial flexibility.
Bottom Line
CADL scores higher overall (22/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Candel Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform, which uniquely targets and destroys cancer cells while preserving healthy tissue. The company has developed a promising pipeline that addresses several challenging malignancies, enhancing the body’s immune response against tumors and striving for significant advancements in therapeutic efficacy. With a solid intellectual property foundation and strategic collaborations with leading research institutions, Candel is well-positioned to be at the forefront of groundbreaking innovations in oncology, with the ultimate goal of improving patient outcomes and reshaping cancer care standards.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?